Hormone-refractory Prostate Cancer

• FDA label_change · 2009-08-20
  FDA Approved: MITOXANTRONE — Supplemental Application (Hospira, Inc.)

  FDA approved a supplemental application for MITOXANTRONE by Hospira, Inc., resulting in updated labeling for the product under the ANDA. The…